Marks the solid execution of FF and FX’s Global Automotive Bridge Strategy in the Middle East, signaling a new phase in the Company’s Middle East Three-Pole strategy and lays a core foundation for future sales. FF and FX will expand Co-Creation initiatives with FX Super One’s first global owner and Developer Co-Creation Officer Andrés Iniesta, accelerating the Middle East’s transition into the new era of EAI-MPV mobility. FX Super One will begin broader deliveries in the UAE, with the goal of becoming the region’s leading MPV.DUBAI, United Arab Emirates, Nov. 27, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (Nasdaq: FFAI) (“Faraday Future,” “FF,” or “the Company”), a global shared intelligent electric mobility ecosystem company headquartered in California, announced today that the Company hosted a Co-Creation...

BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the global Phase II clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of patients with prurigo nodularis in China. Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The Current indications under development are strategically positioned within the vast dermatology market, including atopic dermatitis, vitiligo, prurigo nodularis, urticaria, and more. TYK2 plays a key role in the JAK-STAT signaling pathway and is critical in the pathogenesis of inflammatory diseases. Prurigo...

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease TOKYO and CAMBRIDGE, Mass., Nov. 27, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has filed a new drug application for “LEQEMBI®” (brand name, generic name: lecanemab) seeking approval for a subcutaneous formulation (subcutaneous autoinjector: SC-AI) as a new route of administration to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). The application is based on data from multiple subcutaneous (SC) administration sub-studies of lecanemab conducted...

TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) — Optiva Inc. (TSX: OPT) (“Optiva“) is pleased to announce that the shareholders of Optiva (the “Shareholders“) and the holders (the “Noteholders“) of principal amount of 9.75% senior secured payment-in-kind toggle notes (“PIK Notes“) have approved the proposed plan of arrangement (the “Arrangement“) involving Qvantel Oy (the “Purchaser“) at the special meeting of Shareholders (the “Shareholder Meeting“) and special meeting of Noteholders (the “Noteholder Meeting” and collectively with the Shareholder Meeting, the “Meetings“) held earlier today. Pursuant to the Arrangement, (i) the Purchaser will acquire all of the issued and outstanding common shares of Optiva (the “Shares“)...

VANCOUVER, British Columbia, Nov. 27, 2025 (GLOBE NEWSWIRE) — Mustang Energy Corp. (CSE: MEC, OTC:MECPF, FRA:92T) (the “Company” or “Mustang”) is pleased to announce that it has completed the second tranche of milestone payments to Skyharbour Resources Ltd. (“Skyharbour”) under the option agreement between Mustang and Skyharbour dated November 12, 2024 (the “Option Agreement”) regarding the 914W Uranium Project. Pursuant to the Option Agreement, Mustang paid Skyharbour $20,000 in cash, issued 1,098,901 common shares (each, a “Share”) in the capital of Mustang at a deemed price per Share of $0.091, and completed $100,000 in exploration expenditures on the 914W Uranium Project to satisfy the second tranche of milestone payments. The Shares are subject to a customary hold period expiring on the date that is four months and one day...

VANCOUVER, British Columbia, Nov. 27, 2025 (GLOBE NEWSWIRE) — Western Pacific Trust Company (“WP”) is pleased to announce the appointment of Catherine Schaeffer, currently serving as Manager, Plan Administration to the role of Vice-President, Operations, effective January 1, 2026, subject to regulatory approval. In this new capacity, Ms. Schaeffer will oversee the operational performance and develop continuous improvement initiatives across the organization. With a proven track record in leadership, operational excellence, and team development, Catherine has been instrumental in driving key projects and strengthening organizational effectiveness in her current role. “We are delighted to welcome Cathy into this expanded leadership role. Her deep operational expertise and commitment to our mission will be invaluable as we continue...